Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

141 ARTÍCULOS , VIENDO DEL 1 AL 15

Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease

Marcello A, Wirths O, Schneider-Axmann T, Degerman-Gunnarsson M, Lannfelt L, Bayer TA.

Neurobiol Aging. 2011 Aug;32(8):1379-87. doi: 10.1016/j.neurobiolaging.2009.08.011. Epub 2009 Sep 24.

Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis

Whitwell JL, Jack CR Jr, Przybelski SA, Parisi JE, Senjem ML, Boeve BF, Knopman DS, Petersen RC, Dickson DW, Josephs KA.

Neurobiol Aging. 2011 Sep;32(9):1531-41. doi: 10.1016/j.neurobiolaging.2009.10.012. Epub 2009 Nov 14.

Histological and direct evidence for the role of complement in the neuroinflammation of AD

Veerhuis R.

Curr Alzheimer Res. 2011 Feb;8(1):34-58. doi: 10.2174/156720511794604589.

Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease

Watt AD, Perez KA, Faux NG, Pike KE, Rowe CC, Bourgeat P, Salvado O, Masters CL, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2011;24(1):47-59. doi: 10.3233/JAD-2010-101722.

Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease

Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I.

J Alzheimers Dis. 2011;23(4):717-26. doi: 10.3233/JAD-2010-101527.

Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease

Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV.

J Alzheimers Dis. 2011;24(1):25-34. doi: 10.3233/JAD-2010-101248.

Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease

Schrag M, Crofton A, Zabel M, Jiffry A, Kirsch D, Dickson A, Mao XW, Vinters HV, Domaille DW, Chang CJ, Kirsch W.

J Alzheimers Dis. 2011;24(1):137-49. doi: 10.3233/JAD-2010-101503.

Copper in Alzheimer's disease: a meta-analysis of serum,plasma, and cerebrospinal fluid studies

Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, Siotto M, Rossini PM, Squitti R.

J Alzheimers Dis. 2011;24(1):175-85. doi: 10.3233/JAD-2010-101473.

Metabolome in progression to Alzheimer's disease

Orešič M, Hyötyläinen T, Herukka SK, Sysi-Aho M, Mattila I, Seppänan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lötjönen J, Soininen H.

Transl Psychiatry. 2011 Dec 13;1(12):e57. doi: 10.1038/tp.2011.55.

Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability

Pennisi G, Ferri R, Lanza G, Cantone M, Pennisi M, Puglisi V, Malaguarnera G, Bella R.

J Neural Transm (Vienna). 2011 Apr;118(4):587-98. doi: 10.1007/s00702-010-0554-9. Epub 2011 Jan 5.

New lessons from the Alzheimer's Disease Neuroimaging Initiative

Salloway S.

Arch Neurol. 2011 Jan;68(1):19-21. doi: 10.1001/archneurol.2010.344.

Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease

Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2011 Feb 8;76(6):501-10. doi: 10.1212/WNL.0b013e31820af900. Epub 2011 Jan 12.

Tapping into the biology of Alzheimer disease

Knopman DS.

Neurology. 2011 Feb 8;76(6):496-7. doi: 10.1212/WNL.0b013e31820af995. Epub 2011 Jan 12.

Overview and recent advances in neuropathology. Part 2: Neurodegeneration

Masters CL, Kril JJ, Halliday GM, Pamphlett R, Collins S, Hill AF, McLean C.

Pathology. 2011 Feb;43(2):93-102. doi: 10.1097/PAT.0b013e3283426eee.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias